相似文献
1
Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.
Ann Rheum Dis. 2006 Jan;65(1):7-13. doi: 10.1136/ard.2005.036269. Epub 2005 Jun 7.
2
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
BMJ. 2006 Jun 3;332(7553):1302-8. doi: 10.1136/bmj.332.7553.1302.
3
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Circulation. 2007 Apr 24;115(16):2196-207. doi: 10.1161/CIRCULATIONAHA.106.675991.
4
[Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology].
Presse Med. 2001;30(39-40 Pt 2):70-9.
5
Why do COX-2 inhibitors increase risk of cardiovascular events?
Lancet. 2002 Apr 20;359(9315):1410. doi: 10.1016/S0140-6736(02)08393-9.
6
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Praxis (Bern 1994). 2012 Oct 3;101(20):1309-14. doi: 10.1024/1661-8157/a001074.
7
Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
Stroke. 2003 Nov;34(11):2736-40. doi: 10.1161/01.STR.0000097301.50041.6E. Epub 2003 Oct 23.
8
The pharmacology of selective inhibition of COX-2.
Thromb Haemost. 2006 Oct;96(4):393-400.
9
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Am Heart J. 2003 Oct;146(4):591-604. doi: 10.1016/S0002-8703(03)00398-3.
10
Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events.
FASEB J. 2006 Dec;20(14):2468-75. doi: 10.1096/fj.06-6615com.
引用本文的文献
1
Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
Curr Cardiol Rep. 2021 Jul 16;23(9):120. doi: 10.1007/s11886-021-01560-w.
2
Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation.
Clin Rheumatol. 2018 Apr;37(4):1053-1058. doi: 10.1007/s10067-018-4037-y. Epub 2018 Feb 22.
3
Prevention of stroke in rheumatoid arthritis.
Curr Treat Options Neurol. 2015 Jul;17(7):356. doi: 10.1007/s11940-015-0356-3.
4
Colchicine for secondary prevention of cardiovascular disease.
Curr Atheroscler Rep. 2014 Mar;16(3):391. doi: 10.1007/s11883-013-0391-z.
5
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.
Ther Adv Musculoskelet Dis. 2013 Aug;5(4):166-81. doi: 10.1177/1759720X13491025.
6
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis.
Arthritis Rheum. 2013 Jul;65(7):1675-83. doi: 10.1002/art.37975.
7
Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.
Ther Adv Musculoskelet Dis. 2012 Jun;4(3):149-57. doi: 10.1177/1759720X11436239.
8
Inflammation and shoulder pain--a perspective on rotator cuff disease, adhesive capsulitis, and osteoarthritis: conservative treatment.
Clin Rheumatol. 2009 May;28(5):495-500. doi: 10.1007/s10067-009-1109-z. Epub 2009 Feb 18.
9
Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs.
Wien Med Wochenschr. 2008;158(7-8):195-9. doi: 10.1007/s10354-008-0521-3.
10
The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis.
Curr Rheumatol Rep. 2006 Aug;8(4):255-9. doi: 10.1007/s11926-006-0005-7.
本文引用的文献
1
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
N Engl J Med. 2005 Mar 17;352(11):1081-91. doi: 10.1056/NEJMoa050330. Epub 2005 Feb 15.
2
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
N Engl J Med. 2005 Mar 17;352(11):1071-80. doi: 10.1056/NEJMoa050405. Epub 2005 Feb 15.
3
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med. 2005 Mar 17;352(11):1092-102. doi: 10.1056/NEJMoa050493. Epub 2005 Feb 15.
4
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41. doi: 10.1016/s1542-3565(04)00619-6.
5
Rofecoxib, Merck, and the FDA.
N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8.
6
Rofecoxib, Merck, and the FDA.
N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8.
7
Cardiovascular toxicity of valdecoxib.
N Engl J Med. 2004 Dec 23;351(26):2767. doi: 10.1056/NEJMc045711. Epub 2004 Dec 17.
8
Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction.
Arch Intern Med. 2004;164(22):2472-6. doi: 10.1001/archinte.164.22.2472.
9
COX-2-derived prostacyclin confers atheroprotection on female mice.
Science. 2004 Dec 10;306(5703):1954-7. doi: 10.1126/science.1103333. Epub 2004 Nov 18.
10
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Atherosclerosis. 2004 Dec;177(2):235-43. doi: 10.1016/j.atherosclerosis.2004.10.001.
Zotero 插件